This week, the CSL Ltd (ASX: CSL) share price hit a 52-week low. Should investors view the ASX healthcare share as a buy?

ASX health stocks have fallen this week as Chemist Warehouse hits the bourse through its merger with Sigma Healthcare.

In a report released on February 11, Craig Wong-Pan from RBC Capital maintained a Hold rating on CSL (CMXHF – Research Report), with a price ...

CSL Ltd (ASX: CSL) shares dropped to a 52-week low on Tuesday. Do brokers believe that this is a buying opportunity? Let's ...

Investing.com-- Australian biopharmaceutical giant CSL Ltd (ASX: CSL) reported a rise in half-year net profit, driven ...

Let's see how this biotech giant performed during the first half of FY 2025. The post CSL share price on watch amid $2.1b ...

There were positives and negatives in the company's first half performance. The post CSL shares push higher despite 'mixed ...

The European Commission (EC) has approved Andembry (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

In a report released yesterday, David Stanton from Jefferies maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

CSL's Seqirus vaccine unit saw revenue decline 9% YoY to $1.66 billion for the six months ended December 31, 2024, falling 15% short of analyst expectations. This weakness in the vaccine segment ...